BioVaxys Technology Corp

BioVaxys faces a trading ban amid delayed filings; investors should weigh its malaria vaccine promise against governance gaps and low valuation.

BioVaxys Technology Corp: Vancouver‑based biotech innovating a malaria vaccine and cancer immunotherapy, driving forward global health breakthroughs.

BioVaxys reports promising Phase 1 results for a breast‑cancer vaccine, highlighting its pioneering immunotherapy platform amid financial challenges.

BioVaxys Technology Corp pioneers malaria‑targeting VaxMite vaccine and cancer immunotherapies, aiming to reshape global health with breakthrough biotech solutions.

BioVaxys Technology Corp: Vancouver‑based biotech pioneering malaria vaccine VaxMite, cancer immunotherapies, and global health R&D—track its stock and breakthrough research.

BioVaxys Technology Corp, a Canadian biotech firm, is developing the VaxMite malaria vaccine and exploring cancer immunotherapy, aiming to tackle global health challenges.

BioVaxys Technology Corp. has successfully closed a private placement of unsecured convertible debentures, raising CAD 335,670 in gross proceeds to support the development of its vaccine and immunotherapy pipeline.

BioVaxys Technology Corp. has successfully completed a non-brokered private placement of unsecured convertible debentures, raising $335,670 to fund its research and development activities, particularly the progression of its malaria vaccine, VaxMite.

BioVaxys Technology Corp, a Canadian biotech company, is developing innovative vaccines and immunotherapy products to address global health challenges, including infectious diseases and cancer.

BioVaxys Technology Corp is a Canadian biotech company innovating in global health, developing novel vaccines and therapies for infectious diseases and cancer, with a focus on addressing critical health challenges.